news

CUPERTINO, Calif., Nov. 3, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2014.  Total revenues were $4.3 million and net loss was $7.1 million for the three months ended September 30, 2014,  compared to total revenues of $3.0 million and net loss of $6.0 million for the […]

CUPERTINO, Calif., Oct. 27, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc. (Nasdaq: PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize  REMOXY® (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone.  Pfizer will return

CUPERTINO, Calif., Oct. 24, 2014 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 3, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio

CUPERTINO, Calif., Oct. 10, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at ANESTHESIOLOGY™ 2014, the annual meeting of the American Society of Anesthesiologists (ASA).  The meeting will be held October 11-15, 2014

CUPERTINO, Calif., Aug. 25, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Rodman & Renshaw Investment Conference on Wednesday, September 10  at 10:25 a.m. Eastern Time.  The conference is being held at the New York Palace Hotel in New York City.  A live

CUPERTINO, Calif., Aug. 7, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2014.  Total revenues were $4.6 million and net loss was $5.5 million for the three months ended June 30, 2014 as compared to total revenues of $3.9 million and net loss of $5.1 million for the

CUPERTINO, Calif., July 30, 2014 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, August 7, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio

CUPERTINO, Calif., June 26, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it had entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC, pursuant to which Oxford agreed to make a term loan to the Company in the principal amount of $20 million. The loan has a fixed interest

CUPERTINO, Calif., June 9, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at The 25th Annual Wall Street Analyst Forum Institutional Investor Conference on Thursday, June 19 at 10:35 a.m. Eastern Time.  The conference is being held at the University Club located at 1 West

CUPERTINO, CA, May 16, 2014 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the International Anesthetic Research Society (IARS) Annual Meeting.  The meeting will be held on May 17-20 at the Fairmont Queen